The pharmacological armamentarium for the treatment of SLE is expanding and a number of novel therapies are currently under investigation. In spite of this, steroid therapy remains the cornerstone of treatment and intravenous methylprednisolone (IVMP) is still widely used in clinical practice. There is however surprisingly little evidence on which to define its precise role. The objective of this review was to consider the published evidence relating to the use of IVMP in SLE patients and also to identify open questions that still need to be answered with regard to its use.
In acute flares, IVMP induces rapid suppression of acute inflammation. There is not however a strong evidence base to support the use of high doses compared to low IVMP doses or oral prednisolone. In maintenance regimes, secondary analyses suggest that IVMP may confer additional long-term renal survival over oral steroids as part of a cyclophosphamide regime. Therefore, in addition to the evaluation of novel therapies for SLE, better evidence to define the precise role of IVMP in SLE is still required. (Lupus (2007) 16, 387—393)
Schur P.Systemic lupus erythematosus, in Goldman L , Ausiello D eds. Cecil textbook of medicine, 22nd edition. W.B. Saunders , 2004: 1660—1669.
2.
Tan EM , Cohen AS , Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum, 1982 ; 25: 1271—1277 .
3.
Manzi S.Epidemiology of systemic lupus erythematosus . Am J Manag Care2001; 7: S474—479 .
4.
Mok CC , Lee KW , Ho CT , Lau CS , Wong RWA prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population . Rheumatology ( Oxford ) 2000; 39: 399—406 .
Kurki P.The effects of pulse corticosteroid therapy on the immune system . Scand J Rheumatol1984; 54: 13—15 .
10.
Ioannou Y. , Isenberg DACurrent concepts for the management of systemic lupus erythematosus in adults: a therapeutic challenge . Postgrad Med J2002 ; 78: 599—606 .
11.
Buttgereit F. , da Silva JA , Boers M. et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology . Ann Rheum Dis2002 ; 61: 718—722 .
12.
Mackworth-Young C. , David J. , Morgan S. et al. A double-blind placebo controlled trial of intravenous methylprednisolone in systemic lupus erythematosus . Ann Rheum Dis1988; 47: 496—502 .
13.
Albert D. , Hadler N. , Ropes M.Does corticosteroid therapy affect the survival of patients with SLE?Arthritis Rheum1979; 22: 945—951 .
14.
Liebling M. , McLoughlin K. , Boonsue S. et al. Monthly pulses of methylprednisolone in SLE nephritis . J Rheumatol1981; 9: 543—548 .
15.
Ponticelli C. , Zuchelli P. , Banfi G. et al. Treatment of diffuse proliferative lupus nephritis by intravenous high dose methylprednisolone . Quart J Med1982; 201: 16—24 .
16.
Bertoni M. , Brugnolo F. , Bertoni E. et al. Long term efficacy of high-dose intravenous methylprednisolone pulses in active lupus nephritis . Scand J Rheumatol1993; 23: 82—86 .
17.
Flanc R. , Roberts M. , Strippoli G. et al. Treatment for lupus nehritis . The Cochrane Database of Systematic Reviews2004; Issue 1 CD00292.
18.
Gourley MF , Austin HA 3rd , Scott D. et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial . Ann Intern Med1996; 125: 549—557 .
19.
Illei G. , Austin HA III , Crane M. et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcomes without adding toxicity in patients with lupus nephritis . Ann Intern Med2001; 135: 248—257 .
20.
Houssiau FA , Vasconcelos C. , D'Cruz D. et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomised trial of low dose versus high dose cyclophosphamide . Arthritis Rheum2002; 46: 2121—2131 .
21.
Ginzler EM , Dooley MA , Aranow C. et al. Mycophenalate mofetil or intravenous cyclophoshamide for lupus nephritis . N Engl J Med2005; 353: 2219—2228 .
22.
Kovacs B. , Lafferty T. , Brent L. et al. Transverse Myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature . Ann Rheum Dis2000; 59: 120—124 .
23.
Trevisani V. , Castro A. , Neves JF , Atallah A.Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus . The Cochrane Database of Systematic Reviews2000; Issue 3 CD002265.
24.
Barile-Fabris L. , Ariza-Andraca R. , Olguin-Ortega L. et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus . Ann Rheum Dis2005; 64: 620—625 .
25.
Eyanson S. , Passo M. , Aldo-Benson M. , Benson M.Methylprednisolone pulse therapy for nonrenal lupus erythematosus . Ann Rheum Dis1980; 39: 377—380 .
26.
Lurie D. , Bashar Kahaleh M.Pulse corticosteroid therapy for refractory thrombocytopenia in systemic lupus erythematosus . J Rheumatol1982; 9: 311—313 .
27.
Goldberg J. , Lidskey M.Pulse methylprednisolone therapy for persistent subacute cutaneous lupus . Arthritis Rheum1984; 27: 837—838 .
28.
Isenberg D. , Morrow W. , Snaith M.Methylprednisolone pulse therapy in the treatment of systemic lupus erythematosus . Ann Rheum Dis1982; 4: 347—351 .
29.
Ballou S. , Khan M. , Kushner I.Intravenous pulse methylprednisolone followed by alternate day corticosteroid therapy in lupus erythematosus: a prospective evaluation . J Rheumatology1985; 12: 944—948 .
30.
Edwards J. , Snaith M. , Isenberg D.A double blind controlled trial of methylprednisolone infusions in systemic lupus erythematosus using individualised outcome assessment . Ann Rheum Dis1987; 46: 773—776 .
31.
Badsha H. , Kong KO , Lian TY , Chan SP , Edwards CJ , Chng HHLow-dose pulse methylprednisolone for systemic lupus erythematosus flares is efficacious and has a decreased risk of infectious complications . Lupus2002; 11: 508—513 .
32.
Kong K. , Badsha H. , Lian T.Low-dose pulse methylprednisolone is an effective therapy for severe SLE flares . Lupus2004; 13: 212—213 .
33.
Wollheim F.Acute and long-term complications of corticosteroid pulse therapy . Scand J Rheumatol1984; 54: 27—32 .
34.
Kang I. , Park S.Infectious complications in SLE after immunosuppressive therapies . Curr Opin Rheumatol2003; 15: 528—534 .
35.
Zonana-Nacach A. , Barr S. , Magder L. et al. Damage in systemic lupus erythematosus and its association with corticosteroids . Arthritis Rheum2000; 43: 1801—1808 .
36.
Ibanez D. , Gladman D. , Urowitz M.Adjusted mean systemic lupus erythematosus disease activity index-2 k is a predictor of outcome in SLE . J Rheumatol2005 ; 32: 824—827 .
37.
CellCept.Prescribing information . Roche Laboratories Inc.2005.
38.
Allison AC , Eugui EMMycophenolate mofetil and its mechanisms of action . Immunopharmacology . 2000; 47: 85—118 .
39.
Chan TM , Li FK , Tang CS et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis . Hong Kong - Guangzhou Nephrology Study Group. N Engl J Med2000; 343: 1156—1162 .
40.
Rituxan.Prescribing information . Genentech, Inc. , 2005.
41.
Looney RJ , Anolik JH , Campbell D. et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab . Arthritis Rheum2004; 50: 2580—2589 .
42.
Pyne D. , Ehrenstein M. , Morris V.The therapeutic uses of intravenous immunoglobulins in autoimmune rheumatic diseases . Rheumatology (Oxford) 2002; 41: 367—374 .
43.
Vasoo-S, Thumboo-J, Fong-K-Y. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: disease activity and the use of cytotoxic drugs . Lupus2002; 11: 443—450 .
